金融界9月26日消息，微创医疗在2024年上半年的财务报告显示，公司收入从2023年同期的482,605千美元增加至558,702千美元，增长幅度为15.8%。期间亏损从219,921千美元减少至106,674千美元，下降了51.5%。属于公司股东的亏损也从162,618千美元下降到了96,830千美元，减少了40.5%。基本每股亏损和摊薄每股亏损分别从8.94美分和9.45美分减少到5.29美分和5.63美分，下降幅度分别为40.8%和40.4%。报告期内微创医疗的调整净亏损从185,213千美元下降至68,432千美元，减少了63.1%。微创医疗的主要业务分布在心血管介入、手术机器人、心律管理、骨科医疗器械、外科医疗器械、大动脉及外周血管介入、神经介入以及结构性心脏病等领域上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.